Canaccord Genuity Group Reaffirms Buy Rating for Atara Biotherapeutics (NASDAQ:ATRA)
Canaccord Genuity Group reaffirmed their buy rating on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $13.00 target price on the biotechnology company’s stock. ATRA has been the subject of a number of other research reports. HC Wainwright restated a […]
More Stories
Trump Urges Cuba to Strike Deal With US After Oil, Money Cut Off From Venezuela
By Jacob Burg U.S. President Donald Trump on Jan. 11 told Cuba that it should forge a deal with the...
Wall Street Review: Stocks Close Out Strong Week on Labor Market Clarity
By Panos Mourdoukoutas Equities resumed their rally this week as investors gained a clearer view of the labor market following...
Protests Spread in Iran as Regime Vows to Retaliate Against Any US Attack
By Jacob Burg The Iranian regime threatened on Jan. 11 to strike Israeli and U.S. military bases if Washington attacks...
ICE Agent Involved in Shooting Is Getting Death Threats, Border Czar Says
By Jack Phillips White House border czar Tom Homan defended Immigration and Customs Enforcement (ICE) amid protests against the agency...
Overhauling Air Traffic Control Involves 5,000 Locations and 600 Radar Systems—What to Know
By Jacob Burg The federal government is embarking on what Transportation Secretary Sean Duffy has called “the most important infrastructure...
Trump Calls for Temporary 10 Percent Cap on Credit Card Interest Rates
By Aldgra Fredly President Donald Trump said on Jan. 9 that he would call for a one-year cap on credit...